Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Receivables (2016 - 2025)

Tandem Diabetes Care's Receivables history spans 13 years, with the latest figure at $173.9 million for Q4 2025.

  • For Q4 2025, Receivables rose 51.75% year-over-year to $173.9 million; the TTM value through Dec 2025 reached $173.9 million, up 51.75%, while the annual FY2025 figure was $173.9 million, 51.75% up from the prior year.
  • Receivables reached $173.9 million in Q4 2025 per TNDM's latest filing, up from $125.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $173.9 million in Q4 2025 to a low of $77.2 million in Q1 2021.
  • Average Receivables over 5 years is $107.6 million, with a median of $104.7 million recorded in 2022.
  • Peak YoY movement for Receivables: skyrocketed 75.14% in 2021, then fell 11.07% in 2023.
  • A 5-year view of Receivables shows it stood at $110.7 million in 2021, then grew by 3.61% to $114.7 million in 2022, then fell by 7.99% to $105.6 million in 2023, then increased by 8.55% to $114.6 million in 2024, then surged by 51.75% to $173.9 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Receivables are $173.9 million (Q4 2025), $125.9 million (Q3 2025), and $128.4 million (Q2 2025).